S&P 500   4,185.05 (+0.96%)
DOW   33,106.65 (+0.92%)
QQQ   324.24 (+0.77%)
AAPL   167.45 (+1.27%)
MSFT   285.29 (+0.84%)
META   173.53 (+3.84%)
GOOGL   119.23 (+1.50%)
AMZN   143.85 (+2.17%)
TSLA   905.88 (+4.79%)
NVDA   181.45 (-4.44%)
NIO   20.71 (+2.42%)
BABA   92.40 (-0.17%)
AMD   101.28 (-1.01%)
MU   61.95 (-0.82%)
T   18.27 (-0.44%)
CGC   2.97 (+10.00%)
GE   76.25 (+2.54%)
F   15.76 (+3.01%)
DIS   109.72 (+2.90%)
AMC   26.11 (+17.72%)
PYPL   97.41 (+2.19%)
PFE   49.08 (-0.39%)
NFLX   233.07 (+2.77%)
S&P 500   4,185.05 (+0.96%)
DOW   33,106.65 (+0.92%)
QQQ   324.24 (+0.77%)
AAPL   167.45 (+1.27%)
MSFT   285.29 (+0.84%)
META   173.53 (+3.84%)
GOOGL   119.23 (+1.50%)
AMZN   143.85 (+2.17%)
TSLA   905.88 (+4.79%)
NVDA   181.45 (-4.44%)
NIO   20.71 (+2.42%)
BABA   92.40 (-0.17%)
AMD   101.28 (-1.01%)
MU   61.95 (-0.82%)
T   18.27 (-0.44%)
CGC   2.97 (+10.00%)
GE   76.25 (+2.54%)
F   15.76 (+3.01%)
DIS   109.72 (+2.90%)
AMC   26.11 (+17.72%)
PYPL   97.41 (+2.19%)
PFE   49.08 (-0.39%)
NFLX   233.07 (+2.77%)
S&P 500   4,185.05 (+0.96%)
DOW   33,106.65 (+0.92%)
QQQ   324.24 (+0.77%)
AAPL   167.45 (+1.27%)
MSFT   285.29 (+0.84%)
META   173.53 (+3.84%)
GOOGL   119.23 (+1.50%)
AMZN   143.85 (+2.17%)
TSLA   905.88 (+4.79%)
NVDA   181.45 (-4.44%)
NIO   20.71 (+2.42%)
BABA   92.40 (-0.17%)
AMD   101.28 (-1.01%)
MU   61.95 (-0.82%)
T   18.27 (-0.44%)
CGC   2.97 (+10.00%)
GE   76.25 (+2.54%)
F   15.76 (+3.01%)
DIS   109.72 (+2.90%)
AMC   26.11 (+17.72%)
PYPL   97.41 (+2.19%)
PFE   49.08 (-0.39%)
NFLX   233.07 (+2.77%)
S&P 500   4,185.05 (+0.96%)
DOW   33,106.65 (+0.92%)
QQQ   324.24 (+0.77%)
AAPL   167.45 (+1.27%)
MSFT   285.29 (+0.84%)
META   173.53 (+3.84%)
GOOGL   119.23 (+1.50%)
AMZN   143.85 (+2.17%)
TSLA   905.88 (+4.79%)
NVDA   181.45 (-4.44%)
NIO   20.71 (+2.42%)
BABA   92.40 (-0.17%)
AMD   101.28 (-1.01%)
MU   61.95 (-0.82%)
T   18.27 (-0.44%)
CGC   2.97 (+10.00%)
GE   76.25 (+2.54%)
F   15.76 (+3.01%)
DIS   109.72 (+2.90%)
AMC   26.11 (+17.72%)
PYPL   97.41 (+2.19%)
PFE   49.08 (-0.39%)
NFLX   233.07 (+2.77%)
NASDAQ:TECH

Bio-Techne - TECH Stock Forecast, Price & News

$382.97
-7.93 (-2.03%)
(As of 08/5/2022 03:59 PM ET)
Add
Compare
Today's Range
$373.07
$385.38
50-Day Range
$322.67
$391.85
52-Week Range
$318.07
$543.85
Volume
5,725 shs
Average Volume
255,677 shs
Market Capitalization
$15.03 billion
P/E Ratio
57.85
Dividend Yield
0.33%
Price Target
$489.17

Bio-Techne MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
27.7% Upside
$489.17 Price Target
Short Interest
Healthy
1.98% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.61
Upright™ Environmental Score
News Sentiment
0.02mentions of Bio-Techne in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$2.23 M Sold Last Quarter
Proj. Earnings Growth
16.65%
From $8.35 to $9.74 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.16 out of 5 stars

Medical Sector

13th out of 1,293 stocks

Biological Products, Except Diagnostic Industry

2nd out of 197 stocks

TECH stock logo

About Bio-Techne (NASDAQ:TECH) Stock

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Analyst Ratings Changes

Several equities research analysts have issued reports on TECH shares. KeyCorp dropped their target price on shares of Bio-Techne from $600.00 to $500.00 in a research report on Thursday, May 5th. Wells Fargo & Company lowered shares of Bio-Techne from an "equal weight" rating to an "underweight" rating and lowered their price objective for the stock from $400.00 to $370.00 in a report on Monday, April 25th. Robert W. Baird lowered their price objective on shares of Bio-Techne from $500.00 to $470.00 in a report on Friday. Stephens decreased their target price on shares of Bio-Techne from $500.00 to $480.00 and set an "overweight" rating on the stock in a research note on Friday. Finally, StockNews.com downgraded shares of Bio-Techne from a "buy" rating to a "hold" rating in a research note on Friday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $489.17.

Bio-Techne Price Performance

Shares of TECH opened at $382.97 on Monday. The company has a market capitalization of $15.03 billion, a P/E ratio of 57.85, a price-to-earnings-growth ratio of 1.76 and a beta of 1.22. The company has a quick ratio of 2.79, a current ratio of 3.44 and a debt-to-equity ratio of 0.14. The firm has a 50 day moving average of $357.01 and a 200 day moving average of $386.38. Bio-Techne has a twelve month low of $318.07 and a twelve month high of $543.85.

Bio-Techne (NASDAQ:TECH - Get Rating) last posted its earnings results on Thursday, August 4th. The biotechnology company reported $2.05 EPS for the quarter, missing analysts' consensus estimates of $2.08 by ($0.03). Bio-Techne had a return on equity of 16.97% and a net margin of 24.61%. The company had revenue of $288.30 million during the quarter, compared to the consensus estimate of $287.04 million. During the same period last year, the firm posted $1.67 EPS. The company's revenue for the quarter was up 11.3% on a year-over-year basis. As a group, equities research analysts anticipate that Bio-Techne will post 8.35 earnings per share for the current fiscal year.

Bio-Techne Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 29th. Stockholders of record on Monday, August 15th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date is Friday, August 12th. Bio-Techne's dividend payout ratio (DPR) is 19.34%.

Insider Transactions at Bio-Techne

In other Bio-Techne news, Director Robert V. Baumgartner acquired 300 shares of the company's stock in a transaction that occurred on Tuesday, May 10th. The stock was bought at an average price of $352.55 per share, for a total transaction of $105,765.00. Following the acquisition, the director now directly owns 10,106 shares in the company, valued at $3,562,870.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Charles R. Kummeth sold 5,104 shares of the company's stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $365.00, for a total transaction of $1,862,960.00. Following the transaction, the chief executive officer now directly owns 198,338 shares of the company's stock, valued at approximately $72,393,370. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert V. Baumgartner purchased 300 shares of the company's stock in a transaction on Tuesday, May 10th. The shares were purchased at an average price of $352.55 per share, for a total transaction of $105,765.00. Following the purchase, the director now owns 10,106 shares in the company, valued at approximately $3,562,870.30. The disclosure for this purchase can be found here. Company insiders own 4.10% of the company's stock.

Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Stock News Headlines

Stephens Cuts Bio-Techne (NASDAQ:TECH) Price Target to $480.00
StockNews.com Downgrades Bio-Techne (NASDAQ:TECH) to Hold
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2022 RESULTS
See More Headlines
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Company Calendar

Ex-Dividend for 5/27 Dividend
5/13/2022
Dividend Payable
5/27/2022
Last Earnings
8/04/2022
Today
8/08/2022
Ex-Dividend for 8/29 Dividend
8/12/2022
Dividend Payable
8/29/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:TECH
CUSIP
87837710
Employees
2,600
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$489.17
High Stock Price Forecast
$575.00
Low Stock Price Forecast
$370.00
Forecasted Upside/Downside
+27.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$272.05 million
Pretax Margin
27.26%

Debt

Sales & Book Value

Annual Sales
$1.11 billion
Cash Flow
$9.28 per share
Book Value
$43.36 per share

Miscellaneous

Free Float
37,625,000
Market Cap
$15.03 billion
Optionable
Optionable
Beta
1.22

Social Links















TECH Stock - Frequently Asked Questions

Should I buy or sell Bio-Techne stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bio-Techne stock.
View analyst ratings for Bio-Techne
or view top-rated stocks.

What is Bio-Techne's stock price forecast for 2022?

5 Wall Street analysts have issued 12-month price objectives for Bio-Techne's stock. Their TECH stock forecasts range from $370.00 to $575.00. On average, they predict Bio-Techne's stock price to reach $489.17 in the next twelve months. This suggests a possible upside of 27.7% from the stock's current price.
View analysts' price targets for Bio-Techne
or view top-rated stocks among Wall Street analysts.

How has Bio-Techne's stock performed in 2022?

Bio-Techne's stock was trading at $517.34 at the beginning of the year. Since then, TECH shares have decreased by 26.0% and is now trading at $382.97.
View the best growth stocks for 2022 here
.

When is Bio-Techne's next earnings date?

Bio-Techne is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our earnings forecast for Bio-Techne
.

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) posted its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported $2.05 earnings per share for the quarter, missing the consensus estimate of $2.08 by $0.03. The biotechnology company earned $288.30 million during the quarter, compared to analyst estimates of $287.04 million. Bio-Techne had a net margin of 24.61% and a trailing twelve-month return on equity of 16.97%. The firm's revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.67 earnings per share.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne announced a quarterly dividend on Friday, August 5th. Shareholders of record on Monday, August 15th will be given a dividend of $0.32 per share on Monday, August 29th. This represents a $1.28 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date is Friday, August 12th.
View Bio-Techne's dividend history
.

Is Bio-Techne a good dividend stock?

Bio-Techne(NASDAQ:TECH) pays an annual dividend of $1.28 per share and currently has a dividend yield of 0.33%. The dividend payout ratio of Bio-Techne is 19.34%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 13.14% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.
View Bio-Techne's dividend history.

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne CEO Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among Bio-Techne's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by a number of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (1.22%), Geneva Capital Management LLC (0.65%), Sumitomo Mitsui Trust Holdings Inc. (0.63%), Riverbridge Partners LLC (0.57%), Artemis Investment Management LLP (0.51%) and Stephens Investment Management Group LLC (0.42%). Company insiders that own Bio-Techne stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, Harold J Wiens, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends for Bio-Techne
.

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $382.97.

How much money does Bio-Techne make?

Bio-Techne (NASDAQ:TECH) has a market capitalization of $15.03 billion and generates $1.11 billion in revenue each year. The biotechnology company earns $272.05 million in net income (profit) each year or $6.62 on an earnings per share basis.

How many employees does Bio-Techne have?

Bio-Techne employs 2,600 workers across the globe.

Does Bio-Techne have any subsidiaries?

The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
Read More

When was Bio-Techne founded?

Bio-Techne was founded in 1981.

How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for Bio-Techne is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at ir@bio-techne.com, or via fax at 612-656-4400.

This page (NASDAQ:TECH) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.